A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need. Lanifibranor is a pan-PPAR (peroxisome proliferator-activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH. METHODS: In this phase 2b, double-blind, randomized, placebo-controlled trial, patients with noncirrhotic, highly active NASH were randomly assigned in a 1:1:1 ratio to receive 1200 mg or 800 mg of lanifibranor or placebo once daily for 24 weeks. The primary end point was a decrease of at least 2 points in the SAF-A score (the activity part of the Steatosis, Activity, Fibrosis [SAF] scoring system that incorporates scores for ballooning and inflammation) without worsening of fibrosis; SAF-A scores range from 0 to 4, with higher scores indicating more-severe disease activity. Secondary end points included resolution of NASH and regression of fibrosis. RESULTS: A total of 247 patients underwent randomization, of whom 103 (42%) had type 2 diabetes mellitus and 188 (76%) had significant (moderate) or advanced fibrosis. The percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher among those who received the 1200-mg dose, but not among those who received the 800-mg dose, of lanifibranor than among those who received placebo (1200-mg dose vs. placebo, 55% vs. 33%, P = 0.007; 800-mg dose vs. placebo, 48% vs. 33%, P = 0.07). The results favored both the 1200-mg and 800-mg doses of lanifibranor over placebo for resolution of NASH without worsening of fibrosis (49% and 39%, respectively, vs. 22%), improvement in fibrosis stage of at least 1 without worsening of NASH (48% and 34%, respectively, vs. 29%), and resolution of NASH plus improvement in fibrosis stage of at least 1 (35% and 25%, respectively, vs. 9%). Liver enzyme levels decreased and the levels of the majority of lipid, inflammatory, and fibrosis biomarkers improved in the lanifibranor groups. The dropout rate for adverse events was less than 5% and was similar across the trial groups. Diarrhea, nausea, peripheral edema, anemia, and weight gain occurred more frequently with lanifibranor than with placebo. CONCLUSIONS: In this phase 2b trial involving patients with active NASH, the percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher with the 1200-mg dose of lanifibranor than with placebo. These findings support further assessment of lanifibranor in phase 3 trials. (Funded by Inventiva Pharma; NATIVE ClinicalTrials.gov number, NCT03008070.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both have been tested successfully on phase II clinical trials, proving they are well-tolerated by patients and showing MASH resolution without worsening of fibrosis (165, 166).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [166]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most importantly, resolution of NASH without worsening of fibrosis (49% with 1200 mg Lanifibranor, vs. 39% with 800 mg vs. 22% Placebo), improvement in fibrosis of at least one stage without worsening of NASH (48% vs. 34% vs. 22%) and resolution of NASH plus improvement in fibrosis stage of at least 1 (35% vs. 25% vs. 9%) all favored the study drug as compared to placebo.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [59]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The pan-PPAR agonist lanifibranor demonstrated significant MASH resolution and fibrosis improvement in clinical trials, though it was associated with weight gain [3,136].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [136]
The cited source says what the claim attributes to it.
In the citing paper
“Diarrhea, nausea, peripheral edema, anemia and weight gain were all seen more frequently in patients receiving Lanifibranor [59].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [59]
The cited source says what the claim attributes to it.
In the citing paper
“Finally and most recently the Pan‐PPAR agonist Lanifibranor reached the primary endpoint of a decrease in SAF‐A score of at least two points in a large Phase 2b Trial [59]—a dose‐dependent effect was seen with more patients achieving the primary endpoint with 1200 mg versus 800 mg.”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [59]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationGlobal burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249 · cited 4×
“Increase in aminotransferase level§§ 3 (4) 5 (6) 1 (1)”
InfluentialSelf-citationPioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citationDulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965
Self-citationYounossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)33041-7 · Cited by 1,277
Self-citationNon-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome
Yki-Järvinen, H. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70032-4 · Cited by 1,259 · cited 1×
“Adverse event related to active drug or placebo, during the treatment period, as assessed by the investigator 23 (28) 25 (30) 19 (23)”
Harrison, S. A., Bashir, M. R., Guy, C. D., Zhou, R., Moylan, C. A., Frias, J. P., Alkhouri, N., Bansal, M. B., Baum, S., Neuschwander-Tetri, B. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32517-6 · Cited by 802 · cited 1×
“Adverse event related to active drug or placebo, during the treatment period, as assessed by the investigator 23 (28) 25 (30) 19 (23)”
Self-citationFriedman, S. L., Ratziu, V., Harrison, S. A., Abdelmalek, M. F., Aithal, G. P., Caballeria, J., Francque, S., Farrell, G., Kowdley, K. V., Craxi, A., et al. (2018) · Hepatology · doi:10.1002/hep.29477 · Cited by 671
Self-citation
Research works printed but not linked: 2
- Sanyal AJ, Anstee QM, Trauner M, et al. Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis (NASH). Hepatology 2020; 72: 67A-68A. abstract 90.
- Ratziu V, de Guevara L, Safadi R, et al. Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double- blind, placebo-controlled phase 2b trial. Nat Med (in press).
Cited by
Items 301–400 of 830
Huttman, M. M., Parigi, T. L., Zoncapè, M., Liguori, A., Kalafateli, M., Noel-Storr, A. H., Casazza, G., & Tsochatzis, E. A. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011929.pub2 · Cited by 32
Reprogramming macrophages to treat liver diseases
Simón-Codina, B., Cacho-Pujol, J., Moles, A., & Melgar‐Lesmes, P. (2024) · Hepatology · doi:10.1097/hep.0000000000001160 · Cited by 22
“[91] However, lanifi-branor, a pan-PPAR agonist, has been shown to induce an anti-inflammatory polarization shift in macrophages in preclinical models and succeeded in a phase IIb clinical trial with 247 patients (NCT03008070) [92] (Table 2).”
Bernhard, J., Galli, L., Speidl, W. S., & Krychtiuk, K. A. (2025) · Current Cardiology Reports · doi:10.1007/s11886-024-02185-5 · Cited by 19
“Overall, data on the role of PPAR-agonists in the treatment of MASLD/ MASH is scarce with some potential benefits described [86, 87, 89].”
Adinolfi, L. E., Marrone, A., Rinaldi, L., Nevola, R., Izzi, A., & Sasso, F. C. (2025) · Exploration of Medicine · doi:10.37349/emed.2025.1001281 · Cited by 19
Zhong, J., Cai, Z., Zhu, G., & Zhang, J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16348 · Cited by 18
“47 Additionally, obeticholic acid (OCA), a bile acid receptor agonist, is being evaluated in biopsy-controlled trials (NATIVE study) to assess its impact on MASLD-related fibrosis progression.”
Yoneda, M., Kobayashi, T., Nogami, A., Iwaki, M., Saito, S., & Nakajima, A. (2022) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-21-579 · Cited by 18
Liu, A., Huang, M., Xi, Y., Deng, X., & Xu, K. (2025) · Biomedicines · doi:10.3390/biomedicines13061422 · Cited by 17
Sun, Y., Wu, C., Xin, G., Zhong, B., Wu, X., Liu, Y., Shi, J., Zhang, Q., Zhao, Y., Gao, Y., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001475 · Cited by 20
“[13] Current PPAR agonists, such as saroglita-zar and lanifibranor, have shown efficacy in improving metabolic parameters in MASH patients; [14,15] however, they have yet to receive approval, leaving patients with limited pharmacological options.”
Therapeutics for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
Bhopale, K. K., & Srinivasan, M. P. (2023) · Livers · doi:10.3390/livers3040040 · Cited by 19
Wang, X., Wang, Y., Hou, J., Liu, H., Zeng, R., Li, X., Han, M., Li, Q., Ji, L., Pan, D., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-51210-8 · Cited by 21
“The advantage of a pan-PPAR agonist is its ability to target all three PPAR isoforms (α, γ, and δ), which may enable a more comprehensive and balanced therapeutic effect on glucose and lipid metabolism 22,23 , while also influencing inflammation and fibrogenesis 49 .”
BackgroundNuclear receptors: pathophysiological mechanisms and drug targets in liver disease
Dubois, V., Lefèbvre, P., Staels, B., & Eeckhoute, J. (2024) · Gut · doi:10.1136/gutjnl-2023-331741 · Cited by 18
“77 78 Lanifibranor, an agonist of the three PPAR isotypes, that is, PPARA, PPARG and PPARD, is currently in a phase 3 clinical trial in adults with MASH and liver fibrosis.”
Role of anti-diabetic medications in the management of MASLD
Isaacs, S. D., Farrelly, F. V., & Brennan, P. (2025) · Frontline Gastroenterology · doi:10.1136/flgastro-2024-102856 · Cited by 21
Li, S., Chen, L., & Lv, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.905936 · Cited by 20
“Currently, no effective therapeutics have been approved for it though the pan-PPAR agonist lanifibranor displayed the efficacy in phase 2b trial (Francque et al., 2021).”
BackgroundByrne, C. D. (2022) · Diabetic Medicine · doi:10.1111/dme.14912 · Cited by 18
Ng, N. D., Tai, D., Ren, Y., Chng, E., Seneshaw, M., Mirshahi, F., Idowu, M. O., Asgharpour, A., & Sanyal, A. J. (2023) · Clinical Pathology · doi:10.1177/2632010x231162317 · Cited by 18
Self-citationZeng, X., Zhang, X., Su, H., Gou, H., Lau, H. C.-H., Hu, X., Huang, Z., Li, Y., & Yu, J. Q. (2022) · Engineering · doi:10.1016/j.eng.2022.10.010 · Cited by 16
Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Causation or Association
Bali, A. D., Rosenzveig, A., Frishman, W. H., & Aronow, W. S. (2023) · Cardiology in Review · doi:10.1097/crd.0000000000000537 · Cited by 18
Sanchez, L. O., Zhan, C.-Y., Cauduro, C. G. D. S., Crenier, L., Njimi, H., Englebert, G., Putignano, A., Lepida, A., Degré, D., Boon, N., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100791 · Cited by 21
Self-citationSuárez, M., Martínez, R., Torres, A., Torres, B., & Mateo, J. (2023) · Digestive Diseases and Sciences · doi:10.1007/s10620-023-08031-y · Cited by 17
“These facts could explain the effectiveness of Lanifibranor, a pan-PPAR (Peroxisome Proliferator-Activated Receptor) agonist that have shown promising results in a phase 2b trial by decreasing the fibrosis stage in the 43% of patients treated; Lanifibranor also decreased levels of TG, and it improved glycemic control…”
BackgroundXia, H., Dufour, C. R., Medkour, Y., Scholtes, C., Chen, Y., Guluzian, C., B'Chir, W., & Giguère, V. (2023) · Nature Communications · doi:10.1038/s41467-023-42785-3 · Cited by 17
The keratin-desmosome scaffold of internal epithelia in health and disease – The plot is thickening
Toivola, D. M., Polari, L., Schwerd, T., Schlegel, N., & Strnad, P. (2023) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2023.102282 · Cited by 16
HDL as a Treatment Target: Should We Abandon This Idea?
Bègue, F., Apalama, M. L., Lambert, G. C., & Meilhac, O. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01176-1 · Cited by 16
“Lastly, the pan-PPAR agonist Lanifibranor currently tested in the NATIVE (NASH Trial to Validate IVA337 Efficacy) trial showed positive changes in lipid profile; in particular, it increases HDL-C levels [47].”
Sheng, R., Li, Y., Wu, Y., Liu, C., Wang, W., Han, X., Li, Y., Lei, L., Jiang, X., Zhang, Y., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116220 · Cited by 17
Transcriptomic signatures of progressive and regressive liver fibrosis and portal hypertension
Petrenko, O., Königshofer, P., Brusilovskaya, K., Hofer, B., Bareiner, K., Simbrunner, B., Jühling, F., Baumert, T. F., Lupberger, J., Trauner, M., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109301 · Cited by 20
Pi, D., Zheng, L., Pan, J., Zhen, J., Zheng, C., Fan, W. H., Song, Q., Pan, M., Yang, Q., & Zhang, Y. (2024) · Antioxidants · doi:10.3390/antiox13091026 · Cited by 19
Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom
Knezović, E., Hefer, M., Blažanović, S., Petrović, A., Tomičić, V., Srb, N., Kirner, D., Smolić, R., & Smolić, M. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47030154 · Cited by 19
Liver disease trends in the Asia-Pacific region for the next 50 years
Shiina, S., Maikhuu, J., Qing, D., Batsaikhan, T., Canseco, L. M., Tobari, M., Maruyama, H., Nagamatsu, H., Alcantara‐Payawal, D., Gani, R. A., et al. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0043 · Cited by 19
Sinakos, E., Liava, C., & Loomba, R. (2022) · Annals of Gastroenterology · doi:10.20524/aog.2022.0704 · Cited by 19
Bilson, J., Oquendo, C. J., Read, J., Scorletti, E., Afolabi, P. R., Lord, J., Bindels, L. B., Targher, G., Mahajan, S., Baralle, D., et al. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155759 · Cited by 24
Zhang, Y. L., Yang, J., Min, J., Huang, S. H., Li, Y., & Liu, S. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06255-2 · Cited by 18
Fligor, S. C., Tsikis, S. T., Hirsch, T. I., Pan, A., Moskowitzova, K., Rincón-Cruz, L., Whitlock, A. E., Mitchell, P. D., Nedder, A. P., Gura, K. M., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.05.035 · Cited by 16
Beiriger, J., Chauhan, K., Khan, A., Shahzad, T., Parra, N. S., Zhang, P. G. Y., Chen, S., Nguyen, T. A., Yan, B. M., Bruckbauer, J., et al. (2023) · Livers · doi:10.3390/livers3040042 · Cited by 17
Crosstalk between Lipids and Non-Alcoholic Fatty Liver Disease
Gowda, D., Shekhar, C., Gowda, S. G. B., Chen, Y., & Hui, S. (2023) · Livers · doi:10.3390/livers3040045 · Cited by 15
Wang, Y., He, Y., Sun, W., Yu, H., Tao, W., Yu, X., Jia, D., Liu, Y., Pandol, S. J., & Li, L. (2024) · Drugs · doi:10.1007/s40265-024-02015-6 · Cited by 18
“A total of fifteen trials [11, 13, 18, 19, 23, 41, 43, 48, 51, 54, 58–62] [11], no significant differences were observed between placebo and other regimens.”
InfluentialTrusz, G. J. (2024) · Differentiation · doi:10.1016/j.diff.2024.100793 · Cited by 15
Bril, F., Berg, G. A., Barchuk, M., & Nogueira, J. P. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.1.5 · Cited by 17
Bansal, B., Lajeunesse‐Trempe, F., Keshvani, N., Lavie, C. J., & Pandey, A. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.04.012 · Cited by 28
Recent advances in targeting obesity, with a focus on TGF-β signaling and vagus nerve innervation
John, S., Bhowmick, K., Park, A., Huang, H., Yang, X., & Mishra, L. (2025) · Bioelectronic Medicine · doi:10.1186/s42234-025-00172-x · Cited by 15
Ratziu, V., Surabattula, R., Bugianesi, E., Schattenberg, J. M., Myneni, S. R., Rosso, C., Armandi, A., Pais, R., Kara, L., Charlotte, F., et al. (2025) · Gut · doi:10.1136/gutjnl-2025-335598 · Cited by 15
“6 These data provide clinical relevance to the body of mechanistic evidence linking TSP2 to fibrogenesis and fibrosis accumulation as well as to mechanisms of hepatic inflammation.”
Self-citationYang, M. J., Khoukaz, L., Qi, X., Kimchi, E. T., Staveley-O’Carroll, K. F., & Li, G. (2021) · Biomedicines · doi:10.3390/biomedicines9121893 · Cited by 18
Ampuero, J., Gallego‐Durán, R., Maya‐Miles, D., Montero, R., Gato, S., Rojas, Á., Gil‐Gómez, A., Múñoz‐Hernández, R., & Romero‐Gómez, M. (2022) · Journal of Gastroenterology · doi:10.1007/s00535-022-01860-0 · Cited by 17
“Lanifibranor [37] Sven Francque 2021 IIb N = 247”
BackgroundSelf-citationPotential Therapeutic Targets and Promising Agents for Combating NAFLD
Umemura, A., Kataoka, S., Okuda, K., Seko, Y., Yamaguchi, K., Moriguchi, M., Okanoue, T., & Itoh, Y. (2022) · Biomedicines · doi:10.3390/biomedicines10040901 · Cited by 15
Li, Y., Lei, R., Lei, H., Qin, X., Xie, F., Yao, C., & Feng, P. (2022) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002471 · Cited by 15
Diagnosis and assessment of disease severity in patients with nonalcoholic fatty liver disease
Li, J., Delamarre, A., Wong, V. W., & de Lédinghen, V. (2023) · United European Gastroenterology Journal · doi:10.1002/ueg2.12491 · Cited by 17
“53 Emerging data suggest that these therapeutic agents improve non ‐ invasive tests along with liver histology.”
BackgroundWang, L., Huang, Y., Chen, J., Gao, J., Chen, S., Zhao, M., Lin, J., Zhou, S., Shen, Y., & Cheng, Y. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1635763 · Cited by 27
Macrophage heterogeneity and plasticity in liver injury and repair mechanisms
Zhang, T., Horn, P., Peiseler, M., & Tacke, F. (2025) · Stem Cells · doi:10.1093/stmcls/sxaf072 · Cited by 16
Therapeutic developments in metabolic dysfunction-associated fatty liver disease
Shi, Y., & Fan, J. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002091 · Cited by 17
“Nearly half the patients in the 1200-mg group achieved the primary endpoint, and lanifibranor was well tolerated.([96]) Based on these positive results, lanifibranor received FDA breakthrough therapy designation, and the phase 3 trial among NASH patients with stage F2/F3 fibrosis (NATiV3) is now recruiting (NCT0484972…”
BackgroundGrobbee, E. J., de Jong, V., Schrieks, I. C., Tushuizen, M. E., Holleboom, A. G., Tardif, J., Lincoff, A. M., Schwartz, G. G., Cabezas, M. C., & Grobbee, D. E. (2022) · PLoS ONE · doi:10.1371/journal.pone.0277706 · Cited by 14
“Treatment with lanifibranor, a pan PPAR agonist in patients with severe active NASH led to lowering of a histologically assessed score of NASH activity, also in a subset of diabetic patients [16].”
RetractedTherapeutic targets in alcohol-associated liver disease: progress and challenges
Adekunle, A. D., Adejumo, A., & Singal, A. K. (2023) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231170946 · Cited by 16
Basha, A., May, S. C., Anderson, R. M., Samala, N. R., & Mirmira, R. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129996 · Cited by 18
Raggi, P., Milić, J., Manicardi, M., Cinque, F., Swain, M. G., Sebastiani, G., & Guaraldi, G. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117523 · Cited by 14
Liu, C., Zeng, Q., Hu, T., Huang, Y., Song, Y., Guan, H., Rockey, D. C., Tang, H. C., & Li, S. (2025) · Portal hypertension & cirrhosis · doi:10.1002/poh2.100 · Cited by 15
Rautou, P., Chotkoe, S., Biquard, L., Wettstein, G., van der Graaff, D., Liu, Y., Man, J. D., Casteleyn, C. R., Thys, S., Vos, W. H. D., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101366 · Cited by 23
Self-citationNtikoudi, A., Papachristou, A., Tsalkitzi, A., Margari, N., Evangelou, E., & Vlachou, E. D. (2025) · Diabetology · doi:10.3390/diabetology6040023 · Cited by 15
Targeting Metabolism: Innovative Therapies for MASLD Unveiled
Wang, W., Gao, X., Niu, W., Yin, J., & He, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094077 · Cited by 15
Two sides of the same coin: Non-alcoholic fatty liver disease and atherosclerosis
Zhu, B., Wu, H., Li, K. S., Eisa-Beygi, S., Singh, B., Bielenberg, D. R., Huang, W., & Chen, H. (2023) · Vascular Pharmacology · doi:10.1016/j.vph.2023.107249 · Cited by 15
Is There a Diagnostic Miracle on the Horizon? Emerging Biomarkers in MASLD
Iwaszko-Sochal, K., Kasztelan‐Szczerbińska, B., & Cichoż‐Lach, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176148 · Cited by 14
“…cenicriviroc—the C-C chemokine receptor type 5 (CCR5) inhibitor [37], the peroxisome proliferator-activated receptor (PPAR) agonists–lanifibranor [38] and sarogli-tazar [39], acetyl-coenzyme A (CoA) carboxylase inhibitor–firsocostat [40], apoptosis signal regulator type 1 kinase (ASK1)…”
Tan, Y., Hu, Y., Yang, Y., & Chu, H. (2025) · MedComm · doi:10.1002/mco2.70532 · Cited by 15
Decoding the CHI3L1/IL-13Rα2 signaling nexus in MASH-fibrosis pathogenesis
Zheng, Q., Cao, Y., Jiang, X., Wang, X., Wang, X., He, Y., Ma, W., Wu, H., Jiang, Y., WANG, T., et al. (2025) · Science Advances · doi:10.1126/sciadv.adz3223 · Cited by 14
“…receptor beta (THR β ) agonists (e.g., resmetirom) ( 4 ), and peroxisome proliferator– activated receptor (PPAR) agonists (e.g., lanifibranor) ( 40 ), as well as acetyl-CoA carboxylase/fatty acid synthase (ACC/FAS) inhibitors that regulate lipid metabolism, and farnesoid X receptor agonists (…”
Mitogen-Activated Protein Kinase and Nuclear Hormone Receptor Crosstalk in Cancer Immunotherapy
Burgermeister, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713661 · Cited by 14
Insulin sensitizers in 2023: lessons learned and new avenues for investigation
Colca, J. R., Tanis, S. P., Kletzien, R. F., & Finck, B. N. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2263369 · Cited by 15
“Newer efforts in this approach to attempt selective activation PPARs have resulted in compounds such as elafibranor [16,17], a dual activator of PPARα and PPARδ, and lanifibranor, a pan activator of the three major PPAR subtypes ( αδγ ) [18,19].”
BackgroundHarrison, S. A., Dubourg, J., Knott, M., & Colca, J. R. (2023) · Hepatology · doi:10.1097/hep.0000000000000710 · Cited by 14
Self-citationHove, J. L. K. V., Friederich, M. W., Hock, D. H., Stroud, D. A., Caruana, N. J., Christians, U., Schniedewind, B., Michel, C. R., Reisdorph, R. M., Gonzalez, E. D. J. L., et al. (2024) · Mitochondrion · doi:10.1016/j.mito.2024.101905 · Cited by 13
Breakthrough in the Treatment of Metabolic Associated Steatotic Liver Disease: Is it all over?
Petroni, M. L., Perazza, F., & Marchesini, G. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.04.021 · Cited by 14
Augustijn, Q. J. J., Grefhorst, A., de Groen, P., Wortelboer, K., Seegers, J. F. M. L., Gül, I. S., Suenaert, P., Verheij, J., de Vos, W. M., Herrema, H., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-088290 · Cited by 13
“66 67 Another limitation is the absence of a control group or pure placebo group, which hampers the ability to draw definitive conclusions about the treat-ment’s efficacy.”
Herrera-Ojeda, J. L., Blanco-Palma, R. S., Chávez-Tapia, N. C., Uribe, M., Montalvo-Jave, E. E., & Nuño‐Lámbarri, N. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02621-5 · Cited by 16
“[87, 88].”
Interventions for non-alcoholic liver disease: a gut microbial metabolites perspective
Guo, J., Shi, C., Zhang, Q., Deng, W., Zhang, L., Chen, Q., Zhang, D., & Gong, Z. (2022) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848221138676 · Cited by 16
Subramanian, P., & Chavakis, T. (2023) · The Journal of Physiology · doi:10.1113/jp283820 · Cited by 14
“The pan-PPAR agonist lanifibranor has shown promising results, supporting further investigation (Barreby et al., 2022; Francque et al., 2021).”
BackgroundAmatya, R., Lee, D.-H., Min, K. A., & Shin, M. C. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071963 · Cited by 15
“In a completed phase 2 clinical trial with active NASH patients (Phase 2b Study in NASH to Assess IVA337 (NATIVE), NCT03008070, phase 2), lanifibranor treatment significantly improved the steatosis activity fibrosis (SAF) score and decreased liver enzyme levels and biomarkers of lipid, inflammation, and fibrosis [88].”
BackgroundUpdate on Clinical Trials for Nonalcoholic Steatohepatitis.
Nathani, R. R., & Bansal, M. B. (2023) · PubMed Central · Cited by 21
Nonalcoholic Fatty Liver Disease. Reply.
Sanyal, A. J., Natta, M. L. V., & Tonascia, J. (2022) · PubMed · doi:10.1056/nejmc2118255 · Cited by 4
Self-citationNew horizons in the diagnosis and management of patients with MASLD
van Erpecum, K. J., & Dalekos, G. Ν. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.01.038 · Cited by 14
Laursen, T. L., Mellemkjær, A., Møller, H. J., Grønbæk, H., & Kazankov, K. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2132145 · Cited by 12
Novel regulators of hepatic macrophages in liver fibrosis
Tang, X., Bai, M., Du, X., Wang, H., Liu, M., Fu, X., Zhang, H., Liang, S., & Wang, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1705503 · Cited by 12
Mechanism of oxidized phospholipid-related inflammatory response in vascular ageing
Wang, T., Wang, Y., Zhang, X., Xu, W., Jin, K., Pang, Y., Wu, Y., Luo, J., Xu, R., Jiao, L., et al. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101888 · Cited by 12
Hénin, G., Loumaye, A., Deldicque, L., Leclercq, I. A., & Lanthier, N. (2024) · Liver International · doi:10.1111/liv.15938 · Cited by 12
“28,29 The pathophysiological mechanisms by which physical”
Self-citationZhang, D., Zhao, Y., Zhang, G., Lank, D. S., Cooke, S., Wang, S., Nuotio-Antar, A. M., Tong, X., & Yin, L. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.101957 · Cited by 14
Anastasiou, G., Stefanakis, K., Hill, M. A., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156044 · Cited by 12
Liang, M., Xiao, X., Chen, M., Guo, Y., Han, W., Min, Y., Jiang, X., & Yu, W. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119030 · Cited by 16
Zhu, Z., Guan, Y., Gao, S., Guo, F., Liu, D., & Zhang, H. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117170 · Cited by 12
Current insights in molecular characterization of non-alcoholic fatty liver disease and treatment
Che, W., Zhao, M., Li, X., Li, C., Cho, W. C. S., & Yu, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1002916 · Cited by 14
“Oral intake of 800 or 1,200 mg once daily of lanifibranor for 6 months showed impressive amelioration in steatosis, activity, and fibrosis (SAF) score, ALT, AST level, and markers of apoptosis and steatosis in a phase IIb trial (NCT03008070) (123).”
BackgroundSun, Y., Shen, Y., Liang, X., Zheng, H., & Zhang, Y. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.02.001 · Cited by 13
Future Treatment Options and Regimens for Nonalcoholic Fatty Liver Disease
Francque, S., & Ratziu, V. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.010 · Cited by 13
Self-citationDo Triglyceride-Rich Lipoproteins Equal Low-Density Lipoproteins in Risk of ASCVD?
Wadström, B. N., Wulff, A. B., Pedersen, K. M., & Nordestgaard, B. G. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01153-8 · Cited by 13
Tay, P. W. L., Ng, C. H., Lin, S. Y., Chin, Y. H., Xiao, J., Lim, W. H., Lim, S. Y., Fu, C. E., Chan, K. E., Quek, J., et al. (2022) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002042 · Cited by 12
Self-citationPharmacology and Emerging Therapies for Group 3 Pulmonary Hypertension Due to Chronic Lung Disease
Gonzales, J., & Fraidenburg, D. R. (2023) · Pharmaceuticals · doi:10.3390/ph16030418 · Cited by 12
Marey, M. M., Belal, M. M., Awad, A. A., Rabea, E. M., Hassan, M. A., Abbas, A. W., & Nashwan, A. J. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102357 · Cited by 11
Synthesis and Anti-Liver Fibrosis Research of Aspartic Acid Derivatives
Lv, M., Guo, S., Hexian, Y., Wang, Y., Li, Y., Li, Y., Yi, H., He, H., & Li, Z. (2024) · Molecules · doi:10.3390/molecules29194774 · Cited by 10
MASH to cirrhosis: bridging the gaps in MASLD management
Gadi, Z., Kwanten, W. J., Vonghia, L., & Francque, S. (2024) · Acta Clinica Belgica · doi:10.1080/17843286.2025.2466011 · Cited by 12
“Lanifibranor, a pan-PPAR agonist, demonstrated significant histological improvements in a Phase IIb trial, including reductions in steatosis, inflammation, ballooning, and fibrosis [55].”
Self-citationEffects of polyphenols on non-alcoholic fatty liver disease: a case study of resveratrol
Zhao, Y., Ren, J., Chen, W., Gao, X., Yu, H., Li, X., Zheng, Y., & Yang, J. (2025) · Food & Function · doi:10.1039/d4fo04787g · Cited by 11
Pathogenesis and Clinical Management of Metabolic Dysfunction-Associated Steatotic Liver Disease
Lucaciu, R. L., Coste, S. C., Hangan, A. C., Iancu, M., Orasan, O. H., Cozma, A., Bogdan, S. G., & Procopciuc, L. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125717 · Cited by 14
“It demonstrated a higher activity in reducing the SAF-A score (Steatosis Activity Fibrosis score) by at least two points without deterioration of fibrosis [162].”
Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders
Farrugia, M. A., Pini, E., Tran, A., Chevalier, N., Anty, R., & Gual, P. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00646-8 · Cited by 12
“After 24 weeks, patients treated with 1200 mg of lanifibranor displayed an improvement in MASH without worsening fibrosis, and an improvement in fibrosis of at least 1 stage without worsening MASH compared with placebo group [108].”
FGF21 Analogues and MASLD: A Summary of Preclinical and Clinical Data
Boutari, C., Triantafyllou, A., Papalavrentios, L., Goulis, I., & Sinakos, E. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128374854250709050425 · Cited by 12
Kim, J., BAJAJ, H. S., Ramji, A. S., Bémeur, C., & Sebastiani, G. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.04.003 · Cited by 11
Liu, J., Yang, F., Gao, B., Yang, L., Cao, Y., & Zhou, Y. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01574-w · Cited by 15
“The pan-PPAR agonist lanifibranor has demonstrated dose-dependent improvement in steatohepatitis and fibrosis in a Phase IIb trial, and a Phase III trial (NCT04849728) is currently underway to confirm its efficacy and safety (Francque et al. 2021).”
Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Facts and Hopes
Adinolfi, L. E., Marrone, A., Izzi, A., & Craxì, A. (2025) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2025.103411 · Cited by 11
Immune activation induced by dysregulated lipid metabolism in the pathogenesis of type 2 diabetes
Yang, H., Yu, W., Mao, Q., & Zhao, L. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i12.114395 · Cited by 11
Targeting THR-β for MASLD Treatment: Current Progression and Emerging Prospects
Li, J., Chen, R., Zhang, J., He, J., Wang, Y., & Li, Y. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03114 · Cited by 11
Immune-related pathogenesis and therapeutic strategies of nonalcoholic steatohepatitis
Chung, K. W., Cho, Y. E., Kim, S.-J., & Hwang, S. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01379-1 · Cited by 11
Design of Improved Antidiabetic Drugs: A Journey from Single to Multitarget Agents
Tassopoulou, V., Tzara, A., & Kourounakis, A. P. (2022) · ChemMedChem · doi:10.1002/cmdc.202200320 · Cited by 17
Metadata
- Authors
- Francque, S. M., Bedossa, P., Ratziu, V., Anstee, Q. M., Bugianesi, E., Sanyal, A. J., Loomba, R., Harrison, S. A., Balabanska, R., Mateva, L., Lanthier, N., Alkhouri, N., Moreno, C., Schattenberg, J. M., Stefanova-Petrova, D., Vonghia, L., Rouzier, R., Guillaume, M., Hodge, A., Romero-Gómez, M., Huot-Marchand, P., Baudin, M., Richard, M.-P., Abitbol, J.-L., Broqua, P., Junien, J.-L., & Abdelmalek, M. F.
- Affiliations
- Cliniques Universitaires Saint-Luc (BE)
- From Antwerp University Hospital and the Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp (S.M.F., L.V.), and Service d’Hépato-Gastroentérologie, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (N.L.) and Cliniques Universitaires de Bruxelles–Hôpital Erasme, Université Libre de Bruxelles (C.M.), Brussels — all in Belgium; the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom (P. Bedossa, Q.M.A.); Pitie–Salpétriêre Hospital, Institute of Cardiometabolism and Nutrition, Sorbonne Université, Paris (V.R.), Centre Hospitalier Universitaire Rangueil, Toulouse (M.G.), and Inventiva Pharma, Daix (P.H.-M., M.B., M.-P.R., J.-L.A., P. Broqua, J.-L.J.) — all in France; the Division of Gastroenterology, Department of Medical Sciences, University of Turin, Turin, Italy (E.B.); Virginia Commonwealth University, Richmond (A.J.S.); the University of California San Diego, La Jolla (R.L.); Pinnacle ...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-10-21
- Volume
- 385
- Issue
- 17
- Pages
- 1547-1558
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3207086349
- Cited by
- 801
- References
- 33
- Citations by year
- 2026: 171 · 2025: 197 · 2024: 156 · 2023: 150 · 2022: 119 · 2021: 7
- FWCI
- 77.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- HAL (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Deposito de Investigacion Universidad de Sevilla (University of Seville) (submittedVersion, cc-by-nc-nd)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Inventiva Pharma S.A., Daix, France
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- lanifibranor, nonalcoholic steatohepatitis, liver fibrosis regression, NASH resolution, type 2 diabetes, dose comparison, liver enzymes, PPAR agonists, fibrosis stage
- MeSH terms
- Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Liver Cirrhosis, Male, Middle Aged, Severity of Illness Index, Sulfonamides, Body Mass Index, Peroxisome Proliferator-Activated Receptors, Benzothiazoles, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.